zika
emerg
call
urgent
countermeasur
recent
barrow
et
al
xu
et
al
conduct
vitro
antizikv
screen
identifi
potenti
therapeut
offlabel
use
drug
may
protect
zika
virusinduc
brain
damag
howev
balanc
risk
pregnanc
emerg
neglect
case
zika
forgotten
virus
claim
scene
appar
acceler
speed
exampl
includ
limit
hendra
viru
west
nile
viru
sar
mer
coronavirus
pandem
influenza
ebola
viru
occas
outbreak
author
announc
public
health
emerg
time
neither
scientif
commun
pharmaceut
industri
readi
conquer
problem
outbreak
outbreak
world
taken
surpris
left
without
vaccin
potent
antivir
time
highli
pathogen
viru
emerg
year
need
decad
vaccin
drug
becom
avail
even
acceler
procedur
recent
reemerg
zika
viru
zikv
except
time
pathogen
hit
mostli
vulner
ie
human
fetu
lessler
et
al
safe
effici
zikv
vaccin
becom
avail
mankind
given
lack
specif
antivir
blunt
countermeasur
prevent
treat
infect
viru
attempt
bridg
gap
two
group
recent
conduct
vitro
antizikv
screen
use
set
fdaapprov
drug
barrow
et
al
addit
collect
anoth
druglik
molecul
known
biolog
activ
xu
et
al
barrow
colleagu
employ
imagingbas
approach
compoundpretr
human
hepatoma
cell
infect
zikv
isol
current
outbreak
infect
cultur
fix
hr
infect
fraction
cell
express
zikv
antigen
quantifi
use
approach
molecul
hit
rate
report
inhibit
zikv
replic
antivir
activ
smaller
subset
hit
confirm
cell
deriv
pathophysiolog
relev
tissu
cn
amniot
tissu
xu
et
al
establish
screen
assay
base
previou
observ
zikv
african
lineag
induc
activ
effector
caspas
subsequ
cell
death
within
hr
post
infect
glioblastoma
cell
orthogon
screen
hit
hit
rate
shown
protect
human
neuron
progenitor
cell
viru
activ
molecul
confirm
three
differ
cell
line
includ
astrocyt
set
inhibitor
divid
affect
zikv
replic
ii
agent
protect
infect
cell
death
among
hit
barrow
team
identifi
mycophenol
acid
mpa
activ
compon
immunosuppress
drug
cellcept
antiparasit
drug
ivermectin
report
earlier
inhibit
vitro
flaviviru
replic
mastrangelo
et
al
mefloquin
inhibitor
autophagi
molecul
identifi
studi
antibiot
unknown
mechan
action
daptomycin
proteasom
inhibitor
bortezomib
antidepress
sertalin
drug
affect
nucleosid
metabol
mpa
deplet
dgtp
gtp
pool
dna
synthesi
cellular
signal
molecul
may
serv
good
chemic
probe
aid
understand
biolog
zikv
replic
figur
observ
effect
alreadi
quantifi
hr
infect
timespan
roughli
one
two
full
viral
replic
cycl
take
place
typic
longer
assay
allow
stringent
measur
potenti
antivir
activ
select
almost
molecul
vitro
antivir
activ
accompani
mark
cell
loss
barrow
et
al
point
toward
rather
nonselect
antivir
effect
molecul
exhibit
pronounc
activ
assay
mpa
bortezomid
belong
pregnanc
categori
drug
strictli
contraind
furthermor
also
reason
assum
treatment
immunosuppress
drug
mpa
may
prolong
rather
shorten
viru
persist
drigger
et
al
moreov
depend
concentr
use
compound
antibiot
daptomycin
also
result
unwant
provir
effect
xu
et
al
identifi
possibl
bias
initi
caspas
report
readout
pan
caspaseinhibitor
emricasan
agent
protect
zikvinduc
apoptosi
wherea
emricasan
found
interfer
viral
replic
sever
inhibitor
cyclindepend
kinas
cdki
suppress
express
zikv
protein
viral
progeni
product
figur
pronounc
effect
observ
seliciclib
known
induc
apoptosi
anoth
antihelmint
drug
name
niclosamid
shown
inhibit
zikv
infect
auspici
combin
emricasan
protect
cell
death
niclosamid
inhibit
viral
replic
cdki
reduc
number
infect
cell
number
cell
undergo
concomit
cell
death
among
least
niclosamid
preclud
pregnanc
intriguingli
also
concern
screen
though
use
librari
fdaapprov
drug
report
singl
overlap
hit
may
possibl
extent
explain
use
differ
cell
type
viru
strain
howev
molecul
use
human
prevent
treatment
aggress
viral
infect
exert
activ
mani
cell
linestyp
mani
viral
isol
possibl
also
mention
nucleosid
hepat
c
viru
hcv
polymeras
inhibitor
sofosbuvir
recent
report
inhibit
vitro
replic
zikv
sacramento
et
al
identifi
screen
despit
proof
concept
report
two
studi
believ
one
engag
clinic
trial
offlabel
use
either
fdaapprov
drug
antivir
neuroprotect
potenc
treatment
andor
prevent
zikvinduc
diseas
pregnant
women
consid
pathogenesi
zikv
viru
genom
nt
still
larg
remain
unresolv
enigma
much
deeper
mysteri
vulner
human
fetal
brain
develop
fact
best
inhibitor
identifi
screen
target
major
pathway
cell
homeostasi
apoptosi
cyclindepend
kinas
proteasom
directli
involv
brain
develop
call
extrem
prudenc
zikv
belong
within
famili
flavivirida
genu
flaviviru
includ
wellknown
pathogen
caus
dengu
yellow
fever
west
nile
japanes
enceph
mani
flavivirus
pathogen
man
akin
zikv
new
flavivirus
may
emerg
futur
approv
antivir
infect
flavivirus
despit
fact
annual
estim
million
peopl
develop
dengu
diseas
bhatt
et
al
dengu
second
import
mosquitoborn
diseas
malaria
addit
laudabl
effort
explor
repurpos
exist
drug
aim
develop
dengu
drug
also
endow
panflaviviru
activ
drug
could
besid
employ
treatment
andor
prophylaxi
dengu
use
offlabel
treatment
infect
flavivirus
ie
know
today
also
may
possibl
emerg
near
distant
futur
may
take
field
drug
develop
hcv
anoth
member
famili
flavivirida
exampl
recent
year
highli
potent
welltoler
combin
oral
hcv
inhibitor
develop
allow
typic
patient
cure
within
week
chronic
condit
demonstr
power
potent
directli
act
antivir
hcv
drug
target
uniqu
viral
protein
viral
rnadepend
rna
polymeras
viral
proteas
protein
likewis
flavivirus
encod
protein
less
conserv
within
genu
perfectli
druggabl
kok
lim
et
al
given
suffici
effort
invest
thu
equal
possibl
develop
highli
potent
panflaviviru
inhibitor
would
also
offer
tool
control
zikv
neglect
emerg
flavivirus
likewis
sever
viru
famili
rna
genom
either
highli
pathogen
virus
virus
caus
highli
debilit
condit
belong
avail
vaccin
prevent
drug
treat
infect
includ
exampl
corona
eg
sar
mer
filo
ebola
marburg
alpha
chikungunya
veev
paramyxo
nipah
hendra
entero
bunya
crimean
congo
hemorrhag
fever
rift
valley
fever
hanta
arenavirus
lassa
stand
world
prepar
prevent
combat
next
emerg
viru
quot
dr
chan
directorgener
th
health
assembl
new
diseas
emerg
faster
understand
never
control
world
health
organ
develop
pangenu
panfamili
antivir
help
us
prepar
control
novel
emerg
viral
diseas
debe
et
al
viru
famili
list
encod
uniqu
protein
target
small
molecul
inhibitor
mankind
prepar
expect
unexpect
start
right
effort
aim
right
viralspecif
target
two
drug
repurpos
screen
small
select
fdaapprov
drug
biolog
activ
compound
prove
inhibit
vitro
zikv
replic
ii
protect
infect
cell
death
mani
hit
strictli
contraind
earli
gravid
least
daptomycin
niclosamid
preclud
use
pregnant
women
